Pathogenic bacteria recovered from Gene X-pert tuberculosis-negative adult patients in Gondar, Northwest Ethiopia.
Humans
Adult
Anti-Bacterial Agents
/ pharmacology
Staphylococcus aureus
Methicillin-Resistant Staphylococcus aureus
Escherichia coli
Cefoxitin
Ethiopia
/ epidemiology
Cross-Sectional Studies
Bacteria
Ciprofloxacin
Gram-Negative Bacteria
Gram-Positive Bacteria
Tuberculosis
/ drug therapy
Klebsiella pneumoniae
Gene X-pert
Lower respiratory tract infections
Pathogenic bacteria
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
06 Jun 2023
06 Jun 2023
Historique:
received:
29
11
2022
accepted:
30
05
2023
medline:
8
6
2023
pubmed:
7
6
2023
entrez:
6
6
2023
Statut:
epublish
Résumé
Lower respiratory tract infections (LRTIs) caused by drug-resistant pathogenic bacteria is a major problem in developing countries including Ethiopia. Therefore, this study aimed to determine the pathogenic bacteria and their antimicrobial susceptibility patterns among Gene X-pert tuberculosis-negative adult patients with clinically suspected LRTIs at the University of Gondar Comprehensive Specialized Referral Hospital, Gondar, Northwest Ethiopia. This institutional-based cross-sectional study was conducted from February 01 to March 15, 2020. Socio-demographic data were collected by using a structured questionnaire. A total of 254 sputum specimens were collected from Gene X-pert tuberculosis-negative patients. Bacterial recovery was performed using blood, chocolate, and MacConkey agar plates. Bacterial isolates were identified based on Gram staining, colony characteristics, and biochemical reactions. Antimicrobial susceptibility testing was performed using the Kirby-Bauer disk diffusion method. Methicillin resistance of S. aureus was confirmed using cefoxitin (30 µg). Descriptive statistics were calculated for each variable and results are shown in tables and figures. In this study, the overall sputum culture positivity rate was 145/254 (57.1%). Gram-negative bacteria 111 (64.9%) were predominant compared to Gram-positive bacteria 60 (35.1%). Of the 145 culture-positive cases, 26 (14.8%) had poly-bacterial infections. S. aureus 40 (66.7%) was the predominant Gram-positive bacterium whereas K. pneumoniae 33 (29.7%), was the most isolated Gram-negative bacterium. Bacterial species, such as S. aureus were sensitive to ciprofloxacin 38/40 (95.0%), gentamicin 37/40 (92.5%), cefoxitin 36/40 (90.0%), and clindamycin 34/40 (85.0%). The proportion of Methicillin-resistant S. aureus was low, 4(10.0%). S. pneumoniae was sensitive to chloramphenicol 8/9 (88.9%) and resistant to ciprofloxacin 6/9 (66.7%). K pneumoniae, P. aeruginosa, E. coli, Serratia species, and H. influenzae also demonstrated high levels of resistance to ampicillin at rates of 21/33 (63.6%), 8/8 (100.0%), 15/17 (88.2%), 7/10 (70.0%), and 6/6 (100.0%), respectively. This study revealed a higher burden of Gram-negative and Gram-positive pathogenic bacterial agents, which is responsible for LRTs. Therefore, routine sputum culture identification and antibiotic susceptibility testing should be performed in Gene X-pert tuberculosis-negative patients.
Identifiants
pubmed: 37280538
doi: 10.1186/s12890-023-02500-w
pii: 10.1186/s12890-023-02500-w
pmc: PMC10246094
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cefoxitin
6OEV9DX57Y
Ciprofloxacin
5E8K9I0O4U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
197Informations de copyright
© 2023. The Author(s).
Références
Biomed Res Int. 2019 May 05;2019:8768439
pubmed: 31192259
Open Access Maced J Med Sci. 2019 Jun 30;7(12):1926-1930
pubmed: 31406530
Ann Intern Med. 2016 Mar 15;164(6):425-34
pubmed: 26785402
BMC Infect Dis. 2021 May 13;21(1):440
pubmed: 33985445
Int J Microbiol. 2021 Mar 08;2021:6680343
pubmed: 33763137
Drug Discov Today. 2021 Jan;26(1):31-43
pubmed: 33091564
Open Microbiol J. 2018 Mar 30;12:34-40
pubmed: 29785214
Clin Microbiol Infect. 2019 Jul;25(7):910-911
pubmed: 30910717
Lancet Infect Dis. 2017 Nov;17(11):1133-1161
pubmed: 28843578
Lancet Infect Dis. 2018 Nov;18(11):1191-1210
pubmed: 30243584
Pneumonia (Nathan). 2020 Aug 05;12:7
pubmed: 32775174
Antibiotics (Basel). 2021 Jul 13;10(7):
pubmed: 34356772
J Clin Med Res. 2016 Nov;8(11):831-835
pubmed: 27738486
Iran Biomed J. 2015;19(4):240-6
pubmed: 26220641
J Basic Clin Pharm. 2013 Jun;4(3):51-5
pubmed: 24808671
Arch Intern Med. 1982 Nov;142(12):2157-9
pubmed: 6753779
BMC Proc. 2013 Jul 22;7(Suppl 3):S1
pubmed: 24268075
Thorax. 2013 Nov;68(11):1057-65
pubmed: 24130229
Semin Immunopathol. 2012 Mar;34(2):281-97
pubmed: 22037948
Virusdisease. 2015 Jun;26(1-2):77-81
pubmed: 26436125
Antimicrob Resist Infect Control. 2019 Jun 14;8:101
pubmed: 31223478
Malays J Med Sci. 2011 Apr;18(2):27-31
pubmed: 22135583
BMC Infect Dis. 2013 Feb 20;13:94
pubmed: 23425298
Front Microbiol. 2020 Jun 30;11:1480
pubmed: 32695092
BMJ Open. 2018 Sep 10;8(9):e023592
pubmed: 30206092
Biomed Res Int. 2019 Apr 17;2019:4834396
pubmed: 31119172
J Clin Diagn Res. 2013 Feb;7(2):253-6
pubmed: 23543819
J Clin Diagn Res. 2016 Jan;10(1):DC09-12
pubmed: 26894065
Chin Med J (Engl). 2012 Sep;125(17):2967-72
pubmed: 22932165
Rev Bras Epidemiol. 2017 May;20Suppl 01(Suppl 01):171-181
pubmed: 28658381
J Family Med Prim Care. 2020 Mar 26;9(3):1407-1412
pubmed: 32509624